GP6抗体—艾普蒂 新品

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: K562, Jurkat and 293T cell lysates, Primary antibody: P06575(GP6 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06575(GP6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06575(GP6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GP6 antibody targets glycoprotein VI (GPVI), a critical collagen receptor expressed on platelet surfaces. GPVI plays a central role in platelet activation and thrombus formation by binding to exposed collagen at sites of vascular injury, initiating signaling cascades that promote platelet adhesion, aggregation, and clot stabilization. Structurally, GPVI is a member of the immunoglobulin superfamily, coupled with the Fc receptor γ-chain (FcRγ) to form a signaling complex. Its activation triggers intracellular pathways involving Syk and PLCγ2. ultimately leading to thrombus formation.

GPVI has garnered attention as a therapeutic target due to its specific role in pathological thrombosis while minimally impacting physiological hemostasis. Antibodies against GPVI, such as the monoclonal antibody 9O12. have been explored to inhibit platelet-collagen interactions, offering potential for safer antithrombotic therapies with reduced bleeding risks compared to conventional antiplatelet drugs. Research also highlights GPVI's involvement in inflammatory conditions like rheumatoid arthritis and atherosclerosis, broadening its clinical relevance.

However, GPVI deficiency or polymorphisms in humans (e.g., GPVI mutations) are linked to mild bleeding tendencies, underscoring its balanced role in hemostasis. Current studies focus on optimizing GPVI-targeting biologics, including antibody fragments and fusion proteins, to enhance efficacy and safety. These advancements position GPVI antibodies as promising tools for both understanding thrombotic mechanisms and developing targeted therapies.